Drug Trial Radar · NCT05888831
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jun 6, 2023
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jun 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
BMS-986449Drug
Specified dose on specified days
NivolumabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 4 years
- Number of participants with Adverse Events (AEs)Time frame: Up to approximately 4 years
- Number of participants with Serious Adverse Events (SAEs)Time frame: Up to approximately 4 years
- Number of participants with AEs leading to discontinuationTime frame: Up to approximately 4 years
- Number of deathsTime frame: Up to approximately 4 years
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
Local Institution - 0021
Los Angeles, California
Local Institution - 0007
New Haven, Connecticut
Local Institution - 0010
Hackensack, New Jersey
Local Institution - 0022
Lake Success, New York
Local Institution - 0016
Brussels, Bruxelles-Capitale, Région de, Belgium
Local Institution - 0017
Ghent, Oost-Vlaanderen, Belgium
Local Institution - 0003
Bordeaux, France
Local Institution - 0002
Villejuif, Paris, France
Local Institution - 0004
Marseille, Provence-Alpes-Côte d'Azur Region, France
Local Institution - 0026
Bergamo, Italy
Local Institution - 0025
Roma, Italy
Local Institution - 0023
Rozzano, Milano, Italy
Local Institution - 0024
Siena, Tuscany, Italy
Local Institution - 0018
Groningen, Netherlands
Local Institution - 0030
Amsterdam, North Holland, Netherlands
Local Institution - 0014
Madrid, Spain
Local Institution - 0011
Madrid, Spain
Local Institution - 0015
Málaga, Andalusia, Spain
Local Institution - 0013
Badalona, Barcelona [Barcelona], Spain
Local Institution - 0012
Pamplona, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.